Last 366.80 GBp
Change Today +0.20 / 0.05%
Volume 1.8M
SGE On Other Exchanges
As of 11:35 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

sage group plc/the (SGE) Snapshot

366.50 GBp
Previous Close
366.60 GBp
Day High
366.90 GBp
Day Low
363.60 GBp
52 Week High
02/26/14 - 438.90 GBp
52 Week Low
10/25/13 - 324.20 GBp
Market Cap
Average Volume 10 Days
0.21 GBp
Shares Outstanding
12.84 GBp
Dividend Yield
Current Stock Chart for SAGE GROUP PLC/THE (SGE)

Related News

No related news articles were found.

sage group plc/the (SGE) Related Businessweek News

No Related Businessweek News Found

sage group plc/the (SGE) Details

The Sage Group plc provides business management software and services for small and medium sized businesses. It offers various solutions for accounting, enterprise resource planning, payroll, tax, practice management, accounts production, integrated customer relationship management, business intelligence, and payments. The company serves owners, book keepers, and finance directors. It operates primarily in Europe, the Americas, Africa, Australia, the Middle East, and Asia. The Sage Group plc was founded in 1981 and is headquartered in Newcastle upon Tyne, the United Kingdom.

12,760 Employees
Last Reported Date: 12/4/13
Founded in 1981

sage group plc/the (SGE) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 1.4M GBP
Compensation as of Fiscal Year 2013.

sage group plc/the (SGE) Key Developments

Hemispherx Biopharma and Sage Group Prevails in Multi-Million Dollar Federal Lawsuit

Hemispherx Biopharma, Inc. announced that a federal judge in Delaware has dismissed all claims against Hemispherx and the Sage Group brought by Cato Capital in an order and decision dated September 29, 2014. The decision comes following a three day trial before a judge in the United States District Court for the District of Delaware, which considered several multimillion dollar claims brought by Cato Capital. The Court's order completely vindicated Hemispherx and the Sage Group of any wrongdoing and denied Cato Capital's claims against Hemispherx for breach of contract and fraudulent inducement. On October 14, 2014, Hemispherx' lead trial counsel James J. Black, filed a motion for recovery of fees and costs seeking recovery for Hemispherx of approximately one million dollars based upon contractual fee shifting provisions in the subject contract.

Pluristem Therapeutics, Inc. Announces Strategic Opportunities to Co-Develop and Commercialize its PLacental eXpanded Cell Therapies in Japan

Pluristem Therapeutics Inc. announced that it is evaluating strategic opportunities to co-develop and commercialize its PLacental eXpanded cell therapies in Japan. Recent changes in Japan's laws governing regenerative medicine and the approval of stem cell therapies indicate the country may now offer the fastest track to commercialization in the world for regenerative medicine treatments. As part of the company’s strategy in Japan, on September 16, 2014, company executives presented to a group of Japanese pharmaceutical executives in Tokyo, and conducted a series of one-on-one meetings with Japanese companies exploring a potential partnership with Pluristem. To support its strategy in Japan, the company is working with The Sage Group and Sage's partner Waterfield HealthCom. Pluristem currently has co-development and out-licensing partnership agreements with United Therapeutics and CHA Bio&Diostech.

Update on Government's Exit Of ASIC Registry Unit

A listing of Australian Securities and Investments Commission's registry arm is viewed by many as the most logical exit for the government due to potential sensitivities about confidential corporate data falling into the hands of a private company. While a scoping study will thrash out the various options, many assume the conclusion will be a $3 billion IPO. If a trade sale is pursued, the business is expected to draw a host of potential bidders, including, Computershare Limited (ASX:CPU), Link Market Services Limited, Sage Group plc (LSE:SGE), as well as Dun & Bradstreet Corp. (NYSE:DNB) and Veda. Some have also pointed to potential interest from a revived SAI Global Limited (ASX:SAI). Private equity is also certain to show up in force.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGE:LN 366.80 GBp +0.20

SGE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allscripts Healthcare Solutions Inc $13.62 USD +0.035
athenahealth Inc $117.97 USD +1.93
Micro Focus International PLC 1,014 GBp +6.00
NetSuite Inc $103.61 USD +10.60
Software AG €18.85 EUR -0.039
View Industry Companies

Industry Analysis


Industry Average

Valuation SGE Industry Range
Price/Earnings 17.0x
Price/Sales 2.9x
Price/Book 4.5x
Price/Cash Flow 14.2x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGE GROUP PLC/THE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at